The Molecule of Many Diseases
It is good news when researchers gain a little more knowledge about the development of one disease. It is even better news when that little bit of knowledge applies to a whole group of diseases.
FDA Drug Safety Communication: Tysabri
The U.S. Food and Drug Administration (FDA) continues to evaluate the risk of progressive multifocal leukoencephalopathy ( PML ), a rare but serious brain infection, associated with use of Tysabri ( natalizumab ) for the treatment of multiple sclerosis (MS) and Crohn's disease.